Cyberknife Treatment for Low and Intermediate Risk Prostate Cancer.

Authors :: Detti, B.
Bonomo, P.
Masi, L.
Doro, R.
Cipressi, S.
Iermano, C.
Bonucci, I.
Franceschini, D.
Di Cataldo, V.
Di Brina, L.
Baki, M.
Simontacchi, G.
Meattini, I.
Carini, M.
Serni, S.
Nicita, G.
Livi, L.
Source :: Cancer Investigation; May2015, Vol. 33 Issue 5, p188-192, 5p
Publication Year :: 2015
Abstract: Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer. [ABSTRACT FROM AUTHOR]